-
Mashup Score: 0Chemo + immunotherapy may improve bladder preservation, interim data from phase II study show - The Cancer Letter - 5 day(s) ago
Interim analysis of a clinical trial led by Fox Chase Cancer Center researchers shows promise for the treatment of patients with muscle-invasive bladder cancer. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
E. Gabriela Chiorean, MD, FASCO, highlights the significance of encorafenib plus cetuximab and mFOLFOX6’s FDA approval in BRAF V600E-mutated metastatic CRC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
“Nevertheless, BRAF V600E-mutated CRC tends to be quite aggressive, and overall survival [OS] with first-line chemotherapy, even with FOLFIRINOX plus bevacizumab, is less than 18 months,” said E. Gabriela Chiorean, MD, FASCO, of @fredhutch. #crcsm https://t.co/AtycERbQbU
-
-
Mashup Score: 1Fellowship In Biostatistics (2024-2025) - EORTC - 5 day(s) ago
The EORTC offers a one-year research fellowship (renewable to a maximum of 3 years) to learn the methodology of cancer clinical studies and gain first experience working in this field in an international academic research organization.
Source: www.eortc.orgCategories: General Medicine News, Onc News and JournalsTweet-
📢 Exciting Opportunity! We offer a #ResearchFellowship in #Biostatistics at our #Brussels HQ! 📈📚 Are you passionate about #CancerResearch and #DataAnalysis? Apply now: https://t.co/u4ARHtVAcX #ClinicalTrials #Oncology #Statistics #WorkWithUs https://t.co/9NDhs9Fr19
-
-
Mashup Score: 1GVHD Alliance: Unite to Raise Awareness of GVHD - 5 day(s) ago
The GVHD Alliance supports those who have been diagnosed with GVHD, as well as their loved ones and health care teams.
Source: www.gvhdalliance.orgCategories: General Medicine News, Onc News and JournalsTweet-
The #GVHDAlliance is working to bring awareness of #GVHD to the forefront this #BloodCancerAwarenessMonth. Ready to help us spread the word? Visit https://t.co/rtEACzF4tO for social media downloadables you can share with your network: https://t.co/i40wdeLCKK https://t.co/TfMHahUUeS
-
-
Mashup Score: 0
Marina Konopleva, MD, presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN, demonstrating its potent anti-tumor activity, rapid clearance of peripheral blasts, and restoration of normal hematopoiesis without cumulative myelosuppression.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Tune in to hear Marina Konopleva, MD, of @MontefioreNYC presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN. Watch more here: https://t.co/4axccKAXB9 https://t.co/N06ewp2vEh
-
-
Mashup Score: 0FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma - The Cancer Letter - 5 day(s) ago
FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet-
FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma. https://t.co/f4feQCGLHV
-
-
Mashup Score: 0Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds - The Cancer Letter - 5 day(s) ago
Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet-
Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study (@pfizer) finds. https://t.co/FO5mXFoQ2Q
-
-
Mashup Score: 1Fellowship - EORTC - 9 day(s) ago
Fellowship
Source: www.eortc.orgCategories: General Medicine News, Onc News and JournalsTweet-
🎥 Today is the final #FellowshipFriday! This week we asked our fellows: "What are your goals and dreams?" 👉 Join our fellowship programme: https://t.co/5tnioNZZDT #CancerResearch #EORTCFellowshipProgramme #Fellowship #Careers #ClinicalTrials #Oncology #WorkWithUs https://t.co/bE1B6T1wX3
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 9 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0The Evolutionary Forest of Pancreatic Cancer - 9 day(s) ago
Multiregion-sampled pancreatic cancers representing the full spectrum of clinical presentations reveal distinct genetic differences in pancreatic cancers with indolent features versus those with aggressive metastatic spread.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
Read the paper featured on the cover of this month’s Cancer Discovery: The Evolutionary Forest of #PancreaticCancer https://t.co/X2M8pw3Zvr By @KatelynMullen, @benjraphael, @ciacobu, and colleagues @CpcrMsk @MSKCancerCenter https://t.co/BsIBM4uSe3
-
Chemo + immunotherapy may improve bladder preservation, interim data from phase II study (@FoxChaseCancer) show. https://t.co/lncvQk0Jzl